Therapy with cladribine is efficient and safe in patients previously treated with natalizumab.

Nora MöhnThomas SkripuletzKurt-Wolfram SühsSylvia MenckElke VoßMartin Stangel

Published in: Therapeutic advances in neurological disorders (2019)

In our cohort the switch from natalizumab to cladribine treatment was effective and safe. So far, no serious adverse events other than lymphopenia have been observed, especially no cases of PML.

Keyphrases

multiple sclerosis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
replacement therapy
combination therapy
bone marrow
smoking cessation